A Phase 2 interventional study of Netarsudil Ophthalmic and Netarsudil Ophthalmic in Corneal Edema, sponsored by Aerie Pharmaceuticals. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-15.
Sponsored by Aerie Pharmaceuticals (part of Alcon) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Corneal Edema with a site in United States — 2 open to participants now, 3 under way, 1 of them phase 3. Corneal Edema · United States.
Among the 17 studies in Corneal Edema with a site in United States, this one is the 11th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2020, is one of 2 in phase 2, and was the 5th registered.
39 studies on the registry are indexed under Corneal Edema; 8 are open to participants now.
Browse Corneal Edema studies →2 of the 17 studies in Corneal Edema with a site in United States are open now. Recruiting first, the newest first:
Emmecell · Sites in United States
Ages 21+
University of Miami · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Corneal Edema studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 2 · Phase 4 5
First in 2005; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 52 across 31 interventional studies indexed under Corneal Edema.
Median enrollment 61 across the 14 interventional studies, 55 across the 3 observational. Of the 14 that completed or were terminated, 6 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 17 have an industry lead sponsor. The 10 most frequent:
This study is registered under Aerie Pharmaceuticals, one of the names counted as Alcon. Under that name alone:
Aerie Pharmaceuticals is the lead sponsor of 36 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Alcon has 3 studies filed under Corneal Edema — fewer than ten, so there is no comparison to draw.
3 of the studies in Corneal Edema with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07368959Phase 3Aurion BiotechAURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction | 2027-06 |
| NCT07729137EmmecellStudy of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction | 2027-08 |
| NCT06261346University of MiamiPlasma Rich in Growth Factors in Corneal Endothelial Transplantation | 2027-10-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies in Corneal Edema with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Two different dosing regimens (QD and BID) of netarsudil will be studied to evaluate their efficacy in reducing or resolving corneal edema in subjects with FCD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One drop of Netarsudil 0.02% ophthalmic solution in the study eye in the evening for an 8 week period in up to 20 subjects.
Drug: Netarsudil Ophthalmic
One drop of Netarsudil 0.02% ophthalmic solution in the study eye in the morning and in the evening for an 8 week period in up to 20 subjects.
Drug: Netarsudil Ophthalmic
Netarsudil Ophthalmic Solution 0.02% Topical Sterile Ophthalmic Solution
Also known as: Rhopressa®
Netarsudil Ophthalmic Solution 0.02% Topical Sterile Ophthalmic Solution
Also known as: Rhopressa®
Central Corneal Thickness (CCT)
Mean change from baseline in CCT by ultrasound pachymetry
Time frame: Baseline & 4 weeks
Recruitment took place at 12 clinic sites in the United States between September 2020 and June 2021.
| Milestone | Once Daily Netarsudil Ophthalmic Solution | Twice Daily Netarsudil Ophthalmic Solution |
|---|---|---|
| Started | 20 | 20 |
| Completed | 19 | 19 |
| Not completed | 1 | 1 |
| Milestone | Once Daily Netarsudil Ophthalmic Solution | Twice Daily Netarsudil Ophthalmic Solution |
|---|---|---|
| Started | 20 | 20 |
| Completed | 19 | 19 |
| Not completed | 1 | 1 |
| Milestone | Once Daily Netarsudil Ophthalmic Solution | Twice Daily Netarsudil Ophthalmic Solution |
|---|---|---|
| Started | 18 | 16 |
| Completed | 18 | 15 |
| Not completed | 0 | 1 |
| Milestone | Once Daily Netarsudil Ophthalmic Solution | Twice Daily Netarsudil Ophthalmic Solution |
|---|---|---|
| Started | 20 | 20 |
| Completed | 19 | 19 |
| Not completed | 1 | 1 |
| Withdrew: Adverse event | 1 | 1 |
Mean change from baseline in CCT by ultrasound pachymetry
| µm | Once Daily Netarsudil Ophthalmic Solution | Twice Daily Netarsudil Ophthalmic Solution |
|---|---|---|
| Central Corneal Thickness (CCT) | -28.4 ± 35.72 | -20.1 ± 39.12 |
Collected over Adverse events were documented from the time of signing the informed consent until the last study visit for each participant. This was a period of approximately 8 weeks (56 days) for participants who completed the full study duration. For AEs ongoing at the time of study completion, the ongoing AE was followed-up and the participant was provided appropriate medical care until the event resolved or stabilized, the participant was lost to follow-up, or there was other resolution to the event.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Once Daily Netarsudil Ophthalmic Solution | 0/20 (0%) | 0/20 (0%) | 5/20 (25%) |
| Twice Daily Netarsudil Ophthalmic Solution | 0/20 (0%) | 1/20 (5%) | 7/20 (35%) |
| Event | Once Daily Netarsudil Ophthalmic Solution | Twice Daily Netarsudil Ophthalmic Solution |
|---|---|---|
| Viral gastroenteritisGastrointestinal disorders | 0/20 | 1/20 |
| Event | Once Daily Netarsudil Ophthalmic Solution | Twice Daily Netarsudil Ophthalmic Solution |
|---|---|---|
| Conjunctival hypaeremiaEye disorders | 2/20 | 4/20 |
| Corneal verticillataEye disorders | 3/20 | 2/20 |
| Erythema of eyelidEye disorders | 0/20 | 2/20 |
40 participants were randomized; 20 each to the Netarsudil QD and the Netarsudil BID arms. 1 participant discontinued from each arm due to adverse events. 40 participants were included in both the mITT population for the primary endpoint analysis and the safety population for safety analysis. 6 participants were excluded from the per-protocol analysis due to protocol deviations (2 in the Netarsudil QD arm, 4 in the Netarsudil BID arm). There were no Covid-19 related protocol deviations.
| Age, Categorical(Participants) | Once Daily Netarsudil Ophthalmic Solution | Twice Daily Netarsudil Ophthalmic Solution | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 9 | 9 | 18 |
| >=65 years | 11 | 11 | 22 |
| Sex: Female, Male(Participants) | Once Daily Netarsudil Ophthalmic Solution | Twice Daily Netarsudil Ophthalmic Solution | Total |
|---|---|---|---|
| Female | 9 | 12 | 21 |
| Male | 11 | 8 | 19 |
| Race/Ethnicity, Customized(Participants) | Once Daily Netarsudil Ophthalmic Solution | Twice Daily Netarsudil Ophthalmic Solution | Total |
|---|---|---|---|
| Black/African American | 0 | 2 | 2 |
| White | 20 | 18 | 38 |
| Region of Enrollment(participants) | Once Daily Netarsudil Ophthalmic Solution | Twice Daily Netarsudil Ophthalmic Solution | Total |
|---|---|---|---|
| United States | 20 | 20 | 40 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2020 to primary completion in Aug 2021, 10 months.
Results were first posted in Sep 2022, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Netarsudil